[Controlled trial at Proper-myl treatment in multiple sclerosis].
D000293:Adolescent; D000328:Adult; D000368:Aged; D001688:Biological Products / Q000627:therapeutic use*; D002175:Candida; D003454:Cryptococcus; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007962:Leukocytes / Q000032:analysis; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy*; D010919:Placebos; D012440:Saccharomyces; D013997:Time Factors; D005719:gamma-Globulins / Q000032:analysis
D001688:Biological Products; D010919:Placebos; D005719:gamma-Globulins
Kontrolowana próba stosowania Proper-mylu w stwardnieniu rozsianym.